Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Study Details
Study Description
Brief Summary
This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
Detailed Description
This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.
-
Red cell pyruvate kinase enzyme activity and next-generation sequencing (NGS) hereditary hemolytic anemia panels will be performed on samples from all recruited participants.
-
The study will recruit patients to two separate cohorts.
-
Cohort 1 will recruit approximately 75 anemic (Hgb <11.0 g/dL) MDS participants without overt clinical evidence of hemolysis.
-
Cohort 2 will recruit approximately 25 participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia
-
Participation in the study involves a single blood draw. Basic information about the participant's blood disorder will also be collected.
It is expected that about 100 people will take part in this research study
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cohort I Approximately 75 anemic (Hgb <11.0 g/dL) MDS Participants without overt clinical evidence of hemolysis. - Single Blood Draw |
Procedure: Blood Draw
Blood specimen 2-4 teaspoons
|
| Cohort 2 25 Participants with clonal myeloid disorders of any type with evidence of non-immune, otherwise unexplained hemolytic anemia -Single Blood Draw |
Procedure: Blood Draw
Blood specimen 2-4 teaspoons
|
Outcome Measures
Primary Outcome Measures
- Overall prevalence of possible or likely acquired pyruvate kinase deficiency [Day 1]
defined by PK enzyme activity or PK:HK ratio >1 SD below the control mean (healthy subject mean) as measured by enzyme assay, or potentially pathogenic mutations in the PKLR gene as found on PKLR sequencing
Secondary Outcome Measures
- Overall prevalence of definite acquired pyruvate kinase deficiency [Day 1]
Defined by PK enzyme activity below normal (or a PK:HK ratio <8.7) as measured by enzyme assay, or known pathogenic mutations in the PKLR gene as found on PKLR sequencing
- Red cell pyruvate kinase enzyme activity [60 days]
Red cell pyruvate kinase enzyme activity in patients not receiving red cell transfusion in the 60 days prior to blood draw
- Red cell pyruvate kinase [60 Day]
hexokinase enzyme activity ratio in patients not receiving red cell transfusion in the 60 days prior to blood draw
- Somatic mutations in PKLR (and other genes associated with acquired PKD) detected in the hematopoietic clone [Day 1]
- Somatic mutations in other genes associated with hemolytic anemia detected in the hematopoietic clone [Day 1]
- Characterization of pyruvate kinase-related red cell metabolites (ATP, 2,3-DPG) and pyruvate kinase-R protein in patients with clonal myeloid disorders [Day 1]
- Impact of pyruvate kinase activators on PK activity in vitro [Day 1]
Other Outcome Measures
- Characterization of other possible factors involved in acquired PKD, including acquired epigenetic or gene expression factors [Day 1]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Cohort 1
-
Capable and willing to provide informed consent for participation in the study.
-
Diagnosis of myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN syndrome) according to 2016 World Health Organization (WHO) classification system.
-
Anemia secondary to underlying MDS or MDS/MPN syndrome, defined as a hemoglobin <11.0 g/dL measured within 30 days of study enrollment. Anemia should not be related to nutritional deficiency (such as iron, cobalamin, folate, or copper deficiencies), peripheral immune or non-immune hemolysis, or renal disease, in the opinion of the investigator.
-
Age >18 years.
-
Cohort 2
-
Capable and willing to provide informed consent for participation in the study.
-
Diagnosis of a clonal myeloid neoplasm, such as MDS, MDS/MPN syndrome, myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML), clonal cytopenia of undetermined significance (CCUS), or other clonal myeloid neoplasm according to 2016 World Health Organization (WHO) classification system.
-
A diagnosis of an otherwise unexplained Coombs-negative non-immune hemolytic anemia, according to the clinical judgement of the investigator. Some form of objective laboratory evidence must be present, including one or more of the following: negative direct antiglobulin (Coombs) test, reduced haptoglobin, elevated indirect bilirubin, elevated lactate dehydrogenase, elevated aspartate aminotransferase, or compatible findings on peripheral blood film. Results of all of these tests are not required to satisfy this criterion.
-
Age >18 years.
Exclusion Criteria:
-
Cohort 1
-
Receipt of red cell transfusion within 60 days of study enrollment.
-
Have a known untreated nutritional anemia or acquired disorder resulting in hemolysis, such as paroxysmal nocturnal hemoglobinuria (PNH). A known hereditary anemia (such as thalassemia trait) is not exclusionary if the patient's baseline hemoglobin has worsened significantly (in the opinion of the investigator) after development and diagnosis of MDS.
-
Cohort 2
-
Have a known hereditary anemic disorder, such as thalassemia, sickle cell disease, or hereditary enzyme deficiency, with the exception of hereditary X-linked glucose-6-phosphate dehydrogenase deficiency known not to cause chronic baseline hemolysis. Testing for these diagnoses is not required unless deemed clinically necessary.
-
Have a known untreated nutritional anemia or acquired disorder resulting in hemolysis, such as paroxysmal nocturnal hemoglobinuria (PNH).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Massachusetts General Hospital | Boston | Massachusetts | United States | 02115 |
Sponsors and Collaborators
- Massachusetts General Hospital
- Agios Pharmaceuticals, Inc.
Investigators
- Principal Investigator: Hanny Al-Samkari, MD, Massachusetts General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 21-187